Why the study?
Does epsilon-aminocaproic acid therapy provide sustained antifibrinolytic activity?
Does epsilon-aminocaproic acid therapy provide sustained antifibrinolytic activity?
Epsilon-aminocaproic acid therapy requires three to six days of continuous administration to achieve sustained fibrinolytic inhibition.
Answers are grounded in this paper and cite their sources.
Short courses of epsilon-aminocaproic acid may fail to sustain antifibrinolytic activity; leaves open optimal dosing strategies for clinical use.
Utilizing an in vitro method for activated and nonactivated whole blood clotlysis determinations, the antifibrinolytic effect of epsilon-aminocaproic acid therapy was evaluated. Initially, the induced antifibrinolytic activity diminished within two hours after the previous dose. Continuing therapy for three to six days resulted in sustained fibrinolytic inhibition.
No takes yet. Share an insight, caveat, or question.
Donald W. Nibbelink (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: